Board summary
Key figures
65,449
Registered population
62.3% aged 18–64
10.2%
Aged 65+
ICB 14.9% · England 17.9%
94.2%
In IMD quintile 1
ICB 40.7% · England 21.0%
~49,305
Core20 residents (est.)
Resident basis; registered basis ~62,783 · see page 3
8,214
Hypertension register
+1.53% in 3 yrs · England +5.60%
868
SMI register
29.8% of Oldham (LAD)'s
1,420
COPD register
Reviews +12.08% in 3 yrs
Forecast to 2030
8,499
Hypertension patients, 2030
+285 on today
86.1%
QRISK ≥20% on statins, 2030
+3.90pp over 3 yrs
2.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Preschool MMR2 and booster uptake trails MMR1.
Age-5 MMR1 is 93.4%, but MMR2 is 80.8% (14.2 pp below the 95.0% target, a 12.6 pp same-cohort gap) and 4-in-1 is 79.5%.
Under-80 BP and diabetes HbA1c control lag.
Under-80 BP control fell 0.7% (England +3.2%) to 67.3%, hypertension prevalence is 12.0% (+1.5%), and non-frail diabetes HbA1c <= 58 mmol/mol is 54.4%.
Respiratory reviews and lipid therapy exceed England.
Asthma annual reviews rose +19.0% (England +4.4%) to 76.8%, COPD reviews reached 83.2% (England 76.4%), and QRISK >= 20% lipid therapy reached 77.7%.
Population, age and ethnicity
Registered population is young with 27.5% aged 0-17 against 19.6% across England
Oldham Central PCN serves 65,449 registered patients. The population is young: 27.5% (18,022 patients) are aged 0-17, exceeding Oldham LAD (24.6%), NHS Greater Manchester ICB (21.8%) and England (19.6%). Patients aged 65+ comprise 10.2% (6,652 patients), below Oldham LAD (13.2%), the ICB (14.9%) and England (17.9%). Census usual residents include 0.4% Roma (Oldham LAD 0.2%, ICB 0.1%, England 0.2%) and 0.1% Gypsy or Irish Traveller (Oldham LAD 0.1%, ICB 0.1%, England 0.1%). Registered age counts and resident Census bases cannot be directly combined for service planning.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Oldham (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Oldham LA) | 2,141 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.4% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 54.4% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Oldham LA) | 1,115 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Oldham LA) | 20.9 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
With 94.2% in Core20, deprivation is deeply concentrated across all eleven practices
The PCN has 94.2% of registered patients in the Core20 cohort, compared with 56.7% in Oldham, 40.7% across NHS Greater Manchester ICB, and 21.0% in England, with an average IMD decile of 1.6 (Oldham 3.6, England 5.5). Five practices record 100.0% Core20 concentration, but Glodwick Medical Practice holds the highest volume at 10,529 estimated patients. Registered practice estimates sum to 62,783 (weighted share 95.9%), differing from the 49,305 resident LSOA deciles 1 and 2 estimate. Reconciling registered lists and resident counts is essential before deploying targeted outreach across practices.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
868
SMI register
1.27% recorded prevalence
554
Learning disability register
0.81% recorded prevalence
19
Care homes, 665 beds
In the PCN catchment
9.8%
Provide unpaid care
Oldham (LAD), Census 2021
For OLDHAM CENTRAL PCN, recorded severe mental illness QOF prevalence is 1.3% (868 patients; England 1.0%), and learning disability QOF prevalence is 0.8% (554 patients; England 0.6%). The PCN catchment includes 19 care homes with 665 beds. Higher crude recorded prevalence than national comparators may reflect higher local review demand, though register prevalence does not establish unmet need.
Severe mental illness: physical health checks
Recorded SMI prevalence is 1.3% (England 1.0%). Published individual elements exceed England, with 86.2% BMI recording (England 82.1%) and 84.8% blood pressure checks (England 83.4%); separate element recording does not confirm completed full physical health checks.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,214
Hypertension register
+1.53%
Register growth, 3 yrs
Oldham (LAD) +4.38% · England +5.60%
−0.47pp
BP control, under 80
≤140/90 · −0.21pp aged 80+
+285
More patients by 2030
Forecast 8,499 (12.41%)
Hypertension case-finding and control
Hypertension prevalence is 12.0% (8,214 patients), below Oldham (14.7%) and England (15.2%), with three-year growth of +1.5% trailing England (+5.6%). While recent blood pressure checks reach 91.8% (England 90.0%), blood pressure control to <= 140/90 mmHg for patients under 80 is 67.3% (England 67.8%), falling 0.7% over three years (England +3.2%). Treatment to target is 69.5% (England 70.3%). Unadjusted prevalence does not establish unmet need, and the implied register base differs from the 65,449 list size. Lower blood pressure control under 80 than across England may indicate a need to prioritise systematic recall and medication titration for patients whose blood pressure remains above threshold.
Lipids and statins
Lipid-lowering therapy reaches 77.7% for patients with QRISK >= 20% (England 63.6%), 79.8% in CKD (England 70.3%), and 83.2% in diabetes without cardiovascular disease (England 73.2%). Higher lipid-lowering coverage than England across all risk cohorts provides an opportunity to maintain strong primary prevention reach.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 124,779 | £1.30 | £1.94 | £1.86 | £162,213 |
| Cardiovascular (all), 2025 | 140,493 | £2.62 | £3.15 | £3.33 | £368,092 |
In 2026, the PCN prescribed 124,779 lipid-regulating drug items at £1.30 per item, below Oldham (£1.53) and England (£1.86), spending £69,876 less than at England's unit cost. Unit cost does not measure prescribing efficiency. Lower unit costs than England reflect lower spend per item across prescribed items, though unit cost does not establish prescribing efficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+19.01%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.59%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.0% (England 6.6%), while annual reviews rose +19.0% over three years (England +4.4%) to 76.8% (England 65.7%), though an estimated 1,010 patients on the 4,344 register lack a recorded review. Second-hand smoke status was recorded for 92.0% of asthma patients aged 6-19 (England 78.8%), but asthma prescribing for ages 5-19 was 1,270 items per 1,000 (England 1,488). COPD prevalence is 2.1% (England 1.9%) with reviews reaching 83.2% (England 76.4%), up +12.1% over three years (England +2.8%).
Cancer register and children's immunisation
Cancer prevalence is 2.1% (England 3.8%) with 1,453 patients. Childhood immunisation trails national benchmarks and the 95.0% target. At 12 months, 6-in-1 coverage is 85.8% (England 91.0%), 9.2 pp below the target. At age 5, first-dose MMR reaches 93.4% (England 91.7%), but second-dose MMR falls to 80.8% (England 82.8%), a 12.6 pp dose contrast, while 4-in-1 booster coverage is 79.5% (England 80.9%), leaving preschool booster protection incomplete.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of staged cancers across NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (6,491 of 11,679 with a known stage, with 70.8% known-stage coverage), showing a distance of -19.4 pp to the 75.0% national ambition by 2028 and requiring about 2,270 extra early-stage cases annually across the ICB. At PCN level, cervical screening for women aged 25-49 is 57.2% (England 66.8%), with a 3-year change of -5.9% (England -1.0%), and breast screening coverage is 59.0% (England 69.9%). Crude PCN cancer prevalence is 2.1% (England 3.8%). Lower screening coverage than England across cervical and breast programmes highlights priority areas for PCN recall systems.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Northern Care Alliance NHS Foundation Trust, the distance to the 85.0% 62-day referral to treatment standard is -6.4 pp, while NHS Greater Manchester Integrated Care Board shows a distance of -9.3 pp. On the 28-day faster diagnosis standard (75.0%), the distance is 0.2 pp for the trust and 4.5 pp for the ICB. On the 31-day combined treatment standard (96.0%), the distance is -1.5 pp for the trust and 0.5 pp for the ICB. These provider and ICB measures describe wider system waits, not PCN performance. Secondary care treatment delays at provider level highlight the importance of high-quality urgent.
| Pathways within standard (%) | Northern Care Alliance | Tameside and Glossop Integrated Care | Manchester | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.20 | 82.48 | 80.06 | 79.53 | 79.32 |
| 31-day treatment (96%) | 94.54 | 96.25 | 92.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 78.65 | 76.77 | 72.85 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Northern Care Alliance | Tameside and Glossop Integrated Care | Manchester | England |
|---|---|---|---|---|
| MRI | 5.09 | 0.00 | 11.68 | 21.40 |
| CT | 4.10 | 0.18 | 14.66 | 9.92 |
| Echocardiography | 31.48 | 0.00 | 4.91 | 28.48 |
| Colonoscopy | 40.04 | 1.51 | 4.51 | 30.83 |
| Gastroscopy | 36.48 | 5.45 | 29.35 | 29.02 |
| All 15 DM01 tests | 15.71 | 0.80 | 8.98 | 23.14 |
| Community services activity | Oldham residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 71,440 | 573,310 |
| Referrals | 8,260 | 94,470 |
| Patients with a contact | 17,500 | 183,535 |
Community services (residents of Oldham), Jun 2026 (provisional). Provisional community services data for Oldham residents records 71,440 total contacts, with adults aged 65 and over accounting for 35,720 contacts, representing 50% of all activity. These figures reflect borough-wide resident contacts rather than PCN-level delivery. With adults aged 65 and over representing 50% of community contacts, primary care and community teams must coordinate closely around older patients.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Perkins Practice | 96 | 100.0 | 59.7% | 64.0% | 86.8% |
| St Mary's | 97 | 88.7 | 66.4% | 82.9% | 85.9% |
| John Street | 77 | 96.9 | 48.5% | 72.7% | 80.2% |
| Oldham | 86 | 100.0 | 60.8% | 63.4% | 76.6% |
| Hopwood House | 111 | 90.5 | 49.6% | 65.2% | 76.5% |
| Alexandra Group | 93 | 95.8 | 40.3% | 61.9% | 74.1% |
| Jalal Practice | 81 | 100.0 | 51.7% | 60.4% | 73.8% |
| Lindley House | 83 | 100.0 | 46.0% | 86.2% | 72.6% |
| Chowdhury | 58 | 100.0 | 38.6% | 91.7% | 63.2% |
| Greenbank Medical | 77 | 94.8 | 43.5% | 66.6% | 60.9% |
| Glodwick Medical | 91 | 96.9 | 44.0% | 88.3% | 59.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fifteen of 25 measures trail England over three years despite strong clinical reviews
Over three years, 15 of 25 tracked measures trailed England's trajectory. Relative three-year change was -3.1% (England +5.4%) for learning disability prevalence, -5.9% (England -1.0%) for cervical screening, +1.5% (England +5.6%) for hypertension prevalence, and -0.7% (England +3.2%) for blood pressure control under 80. Conversely, the PCN outperformed national trends in annual reviews: asthma reviews rose +19.0% (England +4.4%), COPD reviews rose +12.1% (England +2.8%), and severe mental illness BMI recording rose +9.4 pp (England +5.1 pp).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Cervical screening
Hypertension register
BP control, under 80
Hypertension treated to target
Asthma reviews
COPD reviews
BMI record (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Oldham (LAD) | Asset | PCN | Oldham (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 19 (665 beds) | n/a | Schools (catchment) | 89 | n/a |
| Children's centres | 8 | 16 | Places of worship | 50 | 127 |
| Libraries | 4 | 10 | Primary schools (LA maintained) | 9 | 42 |
| Primary academies | 15 | 41 | Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Preschool booster and MMR2 catch-up
At age 5 (cohort 229), MMR1 is 93.4% (England 91.7%), while MMR2 is 80.8% (England 82.8%, 14.2 pp below the 95.0% target; 12.6 pp below MMR1) and 4-in-1 is 79.5% (15.5 pp below 95.0%). Moderate effort to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 2
Hypertension BP control and case-finding
Under-80 BP control (<= 140/90 mmHg) is 67.3% (England 67.8%), with 3-year change of -0.7% (England +3.2%). Hypertension prevalence is 12.0% (8,214 patients; England 15.2%), growing +1.5% (England +5.6%). For discussion: practices could run pharmacist-led titration reviews for under-80s above 140/90 mmHg alongside opportunistic BP checks in high-Core20 practices. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Asthma annual review and prescribing follow-up
Asthma annual reviews rose +19.0% over 3 years to 76.8% (England 65.7%), leaving an estimated 1,010 (about 1,000) of 4,344 register patients without a recorded review in the last 12 months. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Paediatric access and capacity review (p2) | Aged 0-17 | Medium Term Planning Framework 2026 · Neighbourhood health framework | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check coordination (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall and titration audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Preschool booster and MMR2 catch-up (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 2 · Hypertension BP control and case-finding (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Asthma annual review and prescribing follow-up (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
